While regulatory concerns over the use of adenoviral vectors in gene therapy trials have received wide attention, the targeted use of such vectors in appropriate indications may have advantages over other therapeutic approaches. For example, researchers at Yale University have published results suggesting that adenoviral-encoded immunoconjugates could be useful to treat cancer. The immunoconjugates were targeted to tumors and tumor vasculature, and may require adenoviral delivery to achieve their therapeutic effect.

In the Proceedings of the National Academy of Sciences, Alan Garen and colleagues at